Use and assessment of PSA in prostate cancer

Medical Clinics of North America

Volumn 95, Issue 1, 2011, Pages 191-200

  Gjertson, Carl K ^a   Albertsen, Peter C ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Mass screening; Prostate; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

MESSENGER RNA; POLYPEPTIDE; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNTRANSLATED RNA;

CANCER DIAGNOSIS; CANCER SCREENING; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DIAGNOSTIC VALUE; DISEASE COURSE; FAMILY HISTORY; HUMAN; LABORATORY TEST; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RACE DIFFERENCE; REVIEW; SCREENING TEST; URINALYSIS;

CONTINENTAL POPULATION GROUPS; EARLY DETECTION OF CANCER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; PRIMARY HEALTH CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 78649370566     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2010.08.024     Document Type: Review

References (44)

1. Balk S.P., Ko Y.J., Bubley G.J. Biology of prostate-specific antigen. J Clin Oncol 2003, 21(2):383-391.
2. Albertsen P.C., Hanley J.A., Barrows G.H., et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005, 97:1248-1253.
3. Stamey T.A., Yang N., Hay A.R., et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987, 317:909-916.
4. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991, 324(17):1156-1161.
5. Smith D.S., Catalona W.J., Herschman J.D. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996, 276(16):1309-1315.
6. Catalona W.J., Smith D.S., Ornstein D.K. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 1997, 277(18):1452-1455.
7. Jhaveri F.M., Klein E.A., Kupelian P.A., et al. Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol 1999, 17:3167-3172.
8. Gjertson C.K., Asher K., Sclar J., et al. Local control and long term disease free survival for D1 prostate cancer following radical prostatectomy in the PSA era. Urology 2007, 70(4):723-727.
9. Etzioni R., Tsodikiv A., Mariotto A., et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 2008, 19:175-181.
10. Collin S.M., Marin R.M., Metcalfe C., et al. Prostate cancer mortality in the USA and UK in 1974-2004: an ecological study. Lancet Oncol 2008, 9:445-452.
11. Grönberg H. Prostate cancer epidemiology. Lancet 2003, 361(9360):859-864.
12. Johansson J.E., Adami H.O., Andersson S.O., et al. Natural history of localized prostatic cancer. A population-based study in 223 untreated patients. Lancet 1989, 1(8642):799-803.
13. Johansson J.E., Adami H.O., Andersson S.O., et al. High 10 year survival rate in patients with early, untreated prostatic cancer. JAMA 1992, 267:2191-2196.
14. Johansson J.E., Holmberg J.S., Bergrstrom R., et al. Fifteen year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997, 277:467-471.
15. Johansson J.E., Andren O., Andersson S.O., et al. Natural history of early, localized prostate cancer. JAMA 2004, 291:2713-2719.
16. Albertsen P.C., Hanley J.A., Gleason D.F., et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998, 280:975-980.
17. Albertsen P.C., Hanley J.A., Fine J. 20 year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293:2095-2101.
18. Bill-Axelson A., Holmber L., Filen F., et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 trial. J Natl Cancer Inst 2008, 100:1144-1154.
19. Widmark A., Klepp O., Solberg A., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial. Lancet 2009, 373:301-308.
20. Andriole G.L., Grubb R.L., Buys S.S., et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-1319.
21. Schroeder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
22. Catalona W.J., Richie J.P., de Kernion J.B., et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994, 152:2031.
23. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998, 279:1542-1547.
24. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges. JAMA 1993, 270:860.
25. Reed A., Ankerst D.P., Pollock B.H., et al. Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer. J Urol 2007, 178:1929-1932.
26. Greene K.L., Albertsen P.A., Babaian R.J., et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009, 182:2232-2241.
27. Carter H.B., Pearson J.D., Metter J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate cancer. JAMA 1992, 177:2215-2220.
28. Carter H.B., Ferrucci L., Ketterman A., et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006, 98:1521-1527.
29. Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the prostate cancer prevention trial. J Natl Cancer Inst 2006, 98:529-534.
30. Vickers A.J., Savage C., O'Brien M.F., et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2008, 27:398-403.
31. American Cancer Society Cancer facts and figures 2005 2005, American Cancer Society, Atlanta (GA).
32. Godley P.A., Schenck A.P., Amamoo A., et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst 2003, 95:1702-1710.
33. Bratt O. Hereditary prostate cancer: clinical aspects. J Urol 2002, 168(3):906-913.
34. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387-2398.
35. Altman D.G., Lausen B., Sauerbrei W., et al. Dangers of using " optimal" cut points in the evaluation of prognostic factors. J Natl Cancer Inst 1994, 86:829-835.
36. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004, 350:2239-2248.
37. Ross A.E., Loeb S., Landis P., et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010, 28(17):2807-2809.
38. Oberpenning F., von Knobloch R., Sprute W., et al. Urologe A 2008, 47:735-739. [in German].
39. Deras I.L., Aubin S.M., Blase A., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008, 179:1587-1592.
40. Schilling D., Hennenlotter J., Munz M., et al. Interpretation of the prostate cancer gene 3 in reference to the individual clinical background: implications for daily practice. Urol Int 2010, 85(2):159-165.
41. Loeb S., Roehl K.A., Antenor J.A., et al. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as a predictor of prostate cancer risk in men younger than 60 years old. Urology 2006, 67:316-320.
42. Screening for prostate cancer U.S. preventive services task force recommendation statement. Ann Intern Med 2008, 149:185-191.
43. Schroeder F.H., Raaijmakers R., Postma R., et al. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam. J Urol 2005, 174:489-494.
44. Wolf A.M., Wender R.C., Etzioni R.B., et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010, 60(2):70-98.